Source comparison
Tesamorelin for Andropause Research: Protocol Comparison
Tesamorelin monotherapy (2mg daily) GHRH analogue stimulating endogenous GH pulsatility 24–52 weeks Visceral fat reduction (10–15%), IGF-1 normalization Does not address testosterone deficiency. Suitable for men with normal testosterone but suppressed GH/IGF-1
This comparison does not assign a generated winner or score.
- Tesamorelin monotherapy (2mg daily)
- GHRH analogue stimulating endogenous GH pulsatility
- 24–52 weeks
- Visceral fat reduction (10–15%), IGF-1 normalization
- Does not address testosterone deficiency. Suitable for men with normal testosterone but suppressed GH/IGF-1
- Testosterone replacement + tesamorelin
- Dual-axis hormonal restoration (HPG + GH)
- Lean mass gain + visceral fat loss + metabolic improvement
- Requires monitoring of IGF-1, glucose, lipids, PSA. Most comprehensive but highest oversight burden
- Exogenous GH (somatropin)
- Direct GH replacement (non-pulsatile)
- 12–24 weeks
- Lean mass gain, fat loss, but with suppression of endogenous GHRH
- Higher cost, requires daily injection, suppresses natural GH axis. Less physiological than tesamorelin
- Testosterone monotherapy
- HPG axis restoration only
- Ongoing (indefinite)
- Lean mass, libido, bone density. Minimal visceral fat impact
- Does not address GH axis decline or insulin resistance in men with metabolic syndrome
- Professional Assessment
- Tesamorelin for andropause research is most compelling when visceral adiposity and insulin resistance are present alongside or independent of testosterone decline. It's a targeted metabolic intervention, not a broad anti-aging therapy.